KalVista Pharmaceuticals (KALV) Competitors $14.04 -0.18 (-1.23%) As of 11:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV vs. MOR, IMVT, HCM, IBRX, AAPG, OGN, APLS, XENE, AMRX, and MIRMShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include MorphoSys (MOR), Immunovant (IMVT), HUTCHMED (HCM), ImmunityBio (IBRX), Ascentage Pharma Group International (AAPG), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. MorphoSys Immunovant HUTCHMED ImmunityBio Ascentage Pharma Group International Organon & Co. Apellis Pharmaceuticals Xenon Pharmaceuticals Amneal Pharmaceuticals Mirum Pharmaceuticals KalVista Pharmaceuticals (NASDAQ:KALV) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment. Does the MarketBeat Community favor KALV or MOR? KalVista Pharmaceuticals received 324 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 74.73% of users gave KalVista Pharmaceuticals an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformKalVista PharmaceuticalsOutperform Votes34974.73% Underperform Votes11825.27% MorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Which has more volatility & risk, KALV or MOR? KalVista Pharmaceuticals has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Which has preferable earnings & valuation, KALV or MOR? KalVista Pharmaceuticals has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$126.64M-$3.72-3.82MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media prefer KALV or MOR? In the previous week, KalVista Pharmaceuticals had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for KalVista Pharmaceuticals and 0 mentions for MorphoSys. KalVista Pharmaceuticals' average media sentiment score of 0.95 beat MorphoSys' score of 0.00 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment KalVista Pharmaceuticals Positive MorphoSys Neutral Is KALV or MOR more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. KalVista Pharmaceuticals' return on equity of -103.92% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -103.92% -88.06% MorphoSys -226.79%-694.31%-22.55% Do insiders and institutionals have more ownership in KALV or MOR? 18.4% of MorphoSys shares are owned by institutional investors. 10.5% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend KALV or MOR? KalVista Pharmaceuticals presently has a consensus target price of $24.83, indicating a potential upside of 74.76%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe KalVista Pharmaceuticals is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryKalVista Pharmaceuticals beats MorphoSys on 13 of the 18 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$688.62M$6.85B$5.58B$8.67BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-3.818.8227.2320.12Price / SalesN/A263.82423.64161.29Price / CashN/A65.8538.2534.64Price / Book2.856.657.114.72Net Income-$126.64M$143.49M$3.23B$247.80M7 Day Performance2.29%4.70%3.67%2.77%1 Month Performance16.39%15.02%13.11%9.75%1 Year Performance13.71%5.96%32.12%15.01% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals3.9534 of 5 stars$14.04-1.2%$24.83+76.9%+18.0%$696.52MN/A-3.85100Insider TradeAnalyst RevisionGap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant1.3948 of 5 stars$16.29-2.9%$38.33+135.3%-34.1%$2.78BN/A-6.22120Positive NewsAnalyst RevisionHCMHUTCHMED1.2799 of 5 stars$15.96+4.0%$19.00+19.0%-6.9%$2.78B$630.20M0.001,760Upcoming EarningsHigh Trading VolumeIBRXImmunityBio1.9585 of 5 stars$3.44+9.2%$12.25+256.1%-46.5%$2.78B$31.22M-3.74590High Trading VolumeAAPGAscentage Pharma Group InternationalN/A$29.88+5.3%N/AN/A$2.60B$980.65M0.00600OGNOrganon & Co.4.9261 of 5 stars$9.76+2.1%$18.00+84.4%-51.5%$2.54B$6.29B2.9310,000Trending NewsAPLSApellis Pharmaceuticals4.6571 of 5 stars$19.39+0.6%$40.05+106.6%-53.0%$2.44B$775.84M-9.55770Analyst RevisionXENEXenon Pharmaceuticals3.4792 of 5 stars$31.45-0.6%$54.82+74.3%-15.9%$2.41B$7.50M-11.15210Analyst RevisionAMRXAmneal Pharmaceuticals3.716 of 5 stars$7.61-0.1%$11.60+52.4%+14.0%$2.39B$2.83B-11.197,600Positive NewsMIRMMirum Pharmaceuticals2.9102 of 5 stars$47.05+1.4%$60.73+29.1%+91.7%$2.33B$379.25M-23.29140Positive NewsAnalyst Revision Related Companies and Tools Related Companies MOR Alternatives IMVT Alternatives HCM Alternatives IBRX Alternatives AAPG Alternatives OGN Alternatives APLS Alternatives XENE Alternatives AMRX Alternatives MIRM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALV) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KALV Stock Free KALV Stock Alerts